<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469806</url>
  </required_header>
  <id_info>
    <org_study_id>04-400</org_study_id>
    <secondary_id>90-112</secondary_id>
    <nct_id>NCT01469806</nct_id>
  </id_info>
  <brief_title>Patello-Femoral Joint Post Market Clinical Follow-up Within the Knee Registry</brief_title>
  <acronym>PFJPMCF</acronym>
  <official_title>Zimmer(R) Gender Solutions(TM) Patello-Femoral Joint Prothesis Used Within the Knee Registry Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the Registry is to allow for tracking of FDA approved and/or cleared&#xD;
      knees used in primary, revision, unicompartmental or partial total knee arthroplasty (TKA).&#xD;
      Second, it is our desire to assist orthopaedic surgeons in obtaining and evaluating&#xD;
      radiographic and functional outcomes data on their PFJ patients using current published&#xD;
      guidelines. Third, within this Registry, subsets of data on newer technology are being&#xD;
      collected for the purpose of future publications. The Patello-Femoral Joint Post Market&#xD;
      Clinical (PFJ PMCF) study is one such subset.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To obtain preoperative, operative and postoperative clinical outcomes data for the Zimmer&#xD;
      Gender Solutions PFJ Knee Prosthesis used in primary partial knee arthroplasty such as knee&#xD;
      scoring and patient satisfaction such collection using Patient Questionaire and SF-12 forms.&#xD;
      Kaplan-Meir survivorship analysis of the device will be performed. Radiographic analysis of&#xD;
      the device will also be performed at 1, 2, 3, 5, 7, and 10 year follow-up. It is planned that&#xD;
      the resultant data will be pooled and published by the evaluating surgeons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Suspended pending internal review/direction of the company's focus. No sites ever engaged or&#xD;
    collected data.&#xD;
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term Device survivorship for publication</measure>
    <time_frame>10 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic analysis of enrolled subjects</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>1 - PFJ</arm_group_label>
    <description>Patients who require primary partial knee arthroplasty of the patello-femoral joint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zimmer Gender Solutions PFJ Knee Prosthesis</intervention_name>
    <description>Partial knee arthroplasty of the patello-femoral joint</description>
    <arm_group_label>1 - PFJ</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient has patellofemoral joint(s) affected by disease process and /or injury and&#xD;
        qualifying for primary unilateral or bilateral replacement of the femoral trochlea based a&#xD;
        primary diagnosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is greater than 18 years of age;&#xD;
&#xD;
          -  Patient selection is without bias to race or gender;&#xD;
&#xD;
          -  Patient is in stable health and able to undergo surgery;&#xD;
&#xD;
          -  Patient has patellofemoral joint(s) affected by disease process and/or injury and&#xD;
             qualifying for primary unilateral or bilateral replacement of the femoral trochlea&#xD;
             based a primary diagnosis of at least one of the following:&#xD;
&#xD;
               -  Osteoarthritis&#xD;
&#xD;
               -  Traumatic Arthritis&#xD;
&#xD;
               -  Polyarthritis&#xD;
&#xD;
               -  Severe Chondrocalcinosis&#xD;
&#xD;
               -  Salvage of previously failed surgical attempts (e.g., arthroscopy, lateral&#xD;
                  release, cartilage transplantation)&#xD;
&#xD;
               -  History of patellar dislocation or patella fracture&#xD;
&#xD;
               -  Dysplasia-induced patellofemoral degeneration&#xD;
&#xD;
          -  Patient is willing and able to cooperate in prescribed post-operative therapy;&#xD;
&#xD;
          -  Patient is willing and able to complete scheduled follow-up evaluations as described&#xD;
             in the Informed Consent;&#xD;
&#xD;
          -  Patient has participated in the Informed Consent process and has signed an IRB&#xD;
             approved Informed Consent.&#xD;
&#xD;
          -  Patient has not history of previous prosthetic replacement device(s) of any type in&#xD;
             the affected knee joint;&#xD;
&#xD;
          -  Independent of study participation, patient is scheduled to receive treatment using a&#xD;
             Zimmer Gender Solutions Patellofemoral Joint Prosthesis (PFJ).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with an acute, chronic, local or systemic infection;&#xD;
&#xD;
          -  Patient is skeletally immature;&#xD;
&#xD;
          -  Patient is pregnant;&#xD;
&#xD;
          -  Patient is a prisoner, mentally incompetent or anticipated to be non-compliant.&#xD;
             Patient has a known allergy to one of the constituents of the implant, e.g. cobalt,&#xD;
             chromium, nickel, etc.;&#xD;
&#xD;
          -  Patient has Rheumatoid Arthritis (RA) AND an ulcer of the skin OR a history of&#xD;
             recurrent breakdown of the skin;&#xD;
&#xD;
          -  Patient has neuropathic arthropathy, neuromuscular disorder, neurologic condition,&#xD;
             vascular disorder, systemic disease and/or other condition that affects lower limb&#xD;
             function and/or could contribute to prosthesis instability, prosthesis fixation&#xD;
             failure, and/or complications in postoperative care;&#xD;
&#xD;
          -  Patient has a Body Mass Index (BMI) greater than 40;&#xD;
&#xD;
          -  Patient has insufficient native bone stock in the operative joint (e.g. osteoporosis,&#xD;
             osteonecrosis, tumors, cysts, etc.). Note: Bone void fillers are NOT considered native&#xD;
             bone stock, even if autograft is used;&#xD;
&#xD;
          -  Patient has severe instability, maltracking, or malalignment of the patella,&#xD;
             patellofemoral, and/or tibiofemoral joints;&#xD;
&#xD;
          -  Patient has patellectomy of the affected joint, including previous patellectomy,&#xD;
             patellectomy performed simultaneous to study PFA, or scheduled patellectomy;&#xD;
&#xD;
          -  Patient has insufficient menisci and/or ligament structures (e.g.&#xD;
             non-functional/absent ACL and/or PCL);&#xD;
&#xD;
          -  Patient exhibits tibiofemoral degeneration and/or Outerbridge grade greater than or&#xD;
             equal to 3 in EITHER:&#xD;
&#xD;
               -  one (medial or lateral) tibiofemoral compartment that is not treated with a&#xD;
                  simultaneous compatible Zimmer unicompartmental knee replacement; OR&#xD;
&#xD;
               -  both (medial AND lateral) tibiofemoral compartments, regardless of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

